

DAFTAR PUSTAKA

1. Ghate K, Amir E, Kuksis M, et al. PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis. *Cancer Treat Rev.* 2019;76(January):51-56.
2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021;71(3):209-249.
3. Kanker di Indonesia Tahun 2014 Data Histopatologik. Jakarta: Badan Registrasi Kanker Perhimpunan Dokter Spesialis Patologi Indonesia; 2018.
4. Miyazaki J, Nishiyama H. Epidemiology of urothelial carcinoma. *Int J Urol.* 2017;24(10):730-734. doi:10.1111/iju.13376
5. Umbas R, Hardjowijoto S, Arif C, Safriadi F, Djatisoesanto W, Sihombing AT. *Panduan Penanganan Kanker Kandung Kemih Tipe Urotelial.* Ikatan Ahli Urologi Indonesia; 2014.
6. Williamson SR, Al-Ahmadie HA, Cheng L. WHO Classification of Tumours of The Urinary System and male Genital Organs. 5th edition. Lyon: International Agency for research On cancer (IARC); 2022.
7. Zhou H, Guo CC, Ro JY. *Urinary Bladder Pathology.* Springer; 2021.
8. Perix VK, Suryanti S, Sihombing AT. Five Years Facts of Bladder Cancer at West Java's Top Referral Hospital, in Indonesia. *Althea Med J.* 2017;4(1):94-99. doi:10.15850/amj.v4n1.1028
9. Kadir MNNA, Hairon SM, Yaacob NM, Manan AA, Ali N. Survival and characteristics of bladder cancer: Analysis of the Malaysian national cancer registry. *Int J Environ Res Public Health.* 2021;18(10). doi:10.3390/ijerph18105237
10. Abdih MA, Djatisoesanto W, Hardjowijoto S. Profile of Bladder Transitional Cell Cancer in Soetomo Hospital Surabaya. *Indones J Urol.* 2014;21(2):1-6. doi:10.32421/juri.v21i2.31
11. Supit W, Mochtar CA, Santoso RB, Umbas R. Outcomes of radical cystectomy and bladder preservation treatment for muscle-invasive urothelial carcinoma of the bladder. *Asian J Surg.* 2014;37(4):184-189. doi:10.1016/j.asjsur.2014.01.010
12. McConkey DJ, Choi W. Molecular Subtypes of Bladder Cancer. *Curr Oncol Rep.* 2018;20(10):1-7.

13. Kwon WA, Seo HK. Optimizing frontline therapy in advanced urothelial cancer. *Transl Androl Urol.* 2020;9(3):983-985. doi:10.21037/tau.2020.04.03
14. Audisio M, Buttiglierio C, Turco F, et al. Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine? *Cells.* 2022;11(10):1-9. doi:10.3390/cells11101614
15. Jiang X, Wang J, Deng X, et al. Role of the tumor microenvironment in PD-L1/PD-1- mediated tumor immune escape. *Mol Cancer.* Published online 2019:1-17.
16. Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: A comprehensive review of registration trials and future considerations. *J Immunother Cancer.* 2018;6(1):1-18. doi:10.1186/s40425-018-0316-z
17. Wang DR, Wu XL, Sun YL. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. *Signal Transduct Target Ther.* 2022;7(1). doi:10.1038/s41392-022-01136-2
18. Huang Y, Zhang SD, McCrudden C, Chan KW, Lin Y, Kwok HF. The prognostic significance of PD-L1 in bladder cancer. *Oncol Rep.* 2015;33(6):3075-3084. doi:10.3892/or.2015.3933
19. Eckstein M, Cimadamore A, Hartmann A, et al. PD-L1 assessment in urothelial carcinoma: a practical approach. *Ann Transl Med.* 2019;7(22):690-690. doi:10.21037/atm.2019.10.24
20. Liu D, Wang S, Bindeman W. Clinical applications of PD-L1 bioassays for cancer immunotherapy. *J Hematol Oncol.* 2017;10(1):1-6. doi:10.1186/s13045-017-0479-y
21. Krohn D. PD-L1 IHC 22C3 pharmDx Interpretation Manual-Urothelial Carcinoma FDA-approved for in vitro diagnostic use.
22. Wen Y, Chen Y, Duan X, et al. The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis. *Clin Exp Med.* 2019;19(4):407-416. doi:10.1007/s10238-019-00572-9
23. Syaebani M, Rinonce HT, Ferronika P, Mada UG. Ekspresi PD-L1 Pada Karsinoma Urotelial Kandung Kemih: Kajian Berdasarkan Umur, Jenis Kelamin, Invasi Otot dan Metastasis Limfonodi. Universitas gadjah Mada. Published online 2021:0-1.
24. Al Nabhani S, Al Harthy A, Al Riyami M, et al. Programmed Death-ligand 1 (PD-L1) Expression in Bladder Cancer and its Correlation with Tumor Grade, Stage, and Outcome. *Oman Med J.* 2022;37(6). doi:10.5001/omj.2022.96

25. Zhou M, Magi-Galluzi. *Genitourinary Pathology*. Philadelphia. Elsevier Saunders;2015
26. Gandhi J, Chen J fu, Al-ahmadie H. Urothelial Carcinoma: Divergent Differentiation and Morphologic Subtypes. 2022;15(4):641-659. doi:10.1016/j.path.2022.07.003.
27. Gaffney CD, Katims A, D'Souza N, Bjurlin MA, Matulewicz RS. Bladder Cancer Carcinogens: Opportunities for Risk Reduction. *Eur Urol Focus*. 2023;9(4):575-578. doi:10.1016/j.euf.2023.03.017
28. Ehdai B, Theodorescu D. Molecular markers in transitional cell carcinoma of the bladder : New insights into mechanisms and prognosis. 2008;(March).
29. Zhao M, He X lei, Teng X dong. Understanding the molecular pathogenesis and prognostics of bladder cancer : an overview. 2016;28(1):92-98. doi:10.3978/j.issn.1000-9604.2016.02.05
30. Netto GJ. Molecular genetics and genomics progress in urothelial bladder cancer. *Semin Diagn Pathol*. 2013;30(4):313-320. doi:10.1053/j.semdp.2013.11.005
31. Knowles M, Hurst C. Molecular biology of bladder cancer : new insights into pathogenesis and clinical diversity. *Nature review*. 2015;15:25-38.
32. Magi-Galluzi C. *Genitourinary Pathology Practical Advances*. Vol 15.; 2019.
33. Raspollini MR, Comperat EM, Lopez-beltran A, et al. News in the classification of WHO 2022 bladder tumors. Published online 2023:32-40. doi:10.32074/1591-951X-838
34. Zang J, Ye K, Fei Y, Zhang R, Chen H, Zhuang G. Immunotherapy in the Treatment of Urothelial Bladder Cancer: Insights From Single-Cell Analysis. *Front Oncol*. 2021;11(May):1-13. doi:10.3389/fonc.2021.696716
35. Babar N, Mushtaq S, Sheikh UN, et al. A clinical and pathologic study of muscle invasive urothelial carcinoma. Does the grade really matter? *Clin Surg Oncol*. 2023;2(3):100022. doi:10.1016/j.cson.2023.100022
36. Petrylak DP. Immunotherapy the wave of the future in bladder cancer. *Clinical genitourinary cancer* 2017 Jun;15(S3-S17). <http://dx.doi.org/10.1016/j.clgc.2017.05.025>
37. Jain RK, Snyders T, Nandgoopal L, Garje R, Zakharia Y, Gupta S. Immunotherapy Advances in Urothelial Carcinoma. *Curr Treat Options Oncol*. 2018;19(12). doi:10.1007/s11864-018-0598-x

38. Abbott M, Aocnp Ò, Ustoyev Y. Cancer and the Immune System : The History and Background of Immunotherapy. *Semin Oncol Nurs.* 2019;35(5):150923. doi:10.1016/j.soncn.2019.08.002
39. Wahid S, Miskad UA. Imunologi lebih mudah dipahami. Diandra Primamitra. 2017
40. Lakshmi B, Kasala N, Reddy E. Immune system : a double-edged sword in cancer. Published online 2013:823-834. doi:10.1007/s00011-013-0645-9
41. Abbas, abul k andrew H litchman. cellular and molecular immunology. *Cohen's Pathw Pulp.* Published online 2021:1680.
42. Menga X ,Lei AY , Xuezhong Zhang. Cancer immunotherapy: Classification, therapeutic mechanisms, and nanomaterial-based synergistic therapy. *Applied Materials Today* 24 (2021) 101149. <https://doi.org/10.1016/j.apmt.2021.101149>
43. Cheng W, Fu D, Xu F, Zhang Z. Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy. *Oncogenesis.* Published online 2018. doi:10.1038/s41389-017-0013-7
44. Rosenblatt JD, Barber GN. *Advances in Tumor Immunology and Immunotherapy.* New york. Springer; 2014.
45. Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. *Nat Rev Drug Discov.* 2019;18(3):175-196. doi:10.1038/s41573-018-0006-z
46. Abbas, A. K; Lichtman, A. H; Pillai S. *Basic Immunology: Functions and Disorders of the Immune System, Sixth Edition.* Vol 110.; 2020.
47. Mendelsohns J, Powis G. *MOLECULAR BASIS OF CANCER.* Philadelphia. Elsevier; 2008.
48. Ju X, Zhang H, Zhou Z, Wang Q. Regulation of PD-L1 expression in cancer and clinical implications in immunotherapy. *Am J Cancer Res.* 2020;10(1):1-11. <http://www.ncbi.nlm.nih.gov/pubmed/32064150><http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7017746>
49. Zhou YJ, Li G, Wang J, et al. PD-L1: expression regulation. *Blood Sci.* 2023;5(2):77-91. doi:10.1097/BS9.000000000000149
50. Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. *Front Pharmacol.* 2017;8(AUG):1-15. doi:10.3389/fphar.2017.00561

51. Zerdes I, Matikas A, Bergh J, Rassidakis GZ, Foukakis T. Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. *Oncogene*. 2018;37(34):4639-4661. doi:10.1038/s41388-018-0303-3
52. Kythreotou A, Siddique A, Mauri F. Gene of the month: PD-L1. *J. Clin Pathol*. 2018; 71: 189-194. doi:10.1136/jclinpath-2017-204853
53. Dermiani FK, Kohlan AK. PD - 1 / PD - L1 immune checkpoint : Potential target for cancer therapy. 2018;(July). doi:10.1002/jcp.27172
54. Pichler R, Heidegger I, Fritz J, et al. PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy Patient characteristics. *ImpactjournalsCom/Oncotarget/*. Published online 2017:1-16.
55. de Jong JJ, Stoop H, Boormans JL, van Leenders GJLH. PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays. *Virchows Arch*. 2021;479(4):705-713. doi:10.1007/s00428-021-03094-6
56. Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. *Cancer Immunol Immunother*. 2007;56(8):1173-1182. doi:10.1007/s00262-006-0266-z
57. Davick JJ, Frierson HF, Smolkin M, Gru AA. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases. *Hum Pathol*. 2018;81:184-191. doi:10.1016/j.humpath.2018.06.028
58. Schulz G, Todorova R, Braunschweig T. PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?. *Urologic Oncology*. 2011 Jun;000 (1-10). <https://doi.org/10.1016/j.urolonc.2021.06.001>.
59. Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. *Onco Targets Ther*. 2016;9:5023-5039. doi:10.2147/OTT.S105862
60. Xu J. *Regulation of Cancer Immune Checkpoints, Molecular and Cellular Mechanisms and Therapy*. Singapore. Springer; 2020.
61. Liu H, Ye T, Yang X, et al. Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis. *Dis Markers*. 2020;2020:1-16. doi:10.1155/2020/8375348
62. Smith V, Mukherjee D, Lunj S, et al. The effect of hypoxia on PD-L1 expression in bladder cancer. *BMC Cancer*. 2021;21(1):1-11. doi:10.1186/s12885-021-

09009-7

63. Hunter BA, Eustace A, Irlam JJ, et al. Expression of hypoxia-inducible factor-1 α predicts benefit from hypoxia modification in invasive bladder cancer. *Br J Cancer*. 2014;111(3):437-443. doi:10.1038/bjc.2014.315
64. Nuryadi, Astuti TD, Utami ES, Budiantara M. *Buku Ajar Dasar-Dasar Statistik Penelitian*; 2017.
65. Saraswati M, Rahaju AS. *Buku Panduan Pemeriksaan Diagnostik Pendamping Untuk Pengobatan Imunoterapi*. Perhimpunan Dokter Spesialis Patologi Anatomi Indonesia. 2023.
66. Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of Bladder Cancer. *Med Sci (Basel, Switzerland)*. 2020;8(1):1-12. doi:10.3390/medsci8010015
67. Kumar V, Abbas AK, Aster JC, editors. *Robbins and Cotran Pathologic Basis Of Disease*. Ninth edition. Philadelphia: Elsevier; 2015.
68. Burger M, Catto JWF, Dalbagni G, et al. Epidemiology and Risk Factors of Urothelial Bladder Cancer. *Eur Urol*. Published online 2012:1-8. doi:10.1016/j.eururo.2012.07.033
69. Omorphos NP, Carlo J, Piedad P. Guideline of guidelines : Muscle-invasive bladder cancer. 2021;47:71-78. doi:10.5152/tud.2020.20337
70. Dwi AH, Rinonce HT, Ferronika P. Hubungan Ekspresi PD-L1 Dengan Grading Tumor, Indeks Proliferasi, Dan Tumor- Infiltrating Lymphocytes (TILs) Pada Karsinoma Urotelial Kandung Kemih. Universitas Gadjah Mada. Published online 2021:0-2.
71. Tretiacova M, Fulton R. Concordance study of pd-11 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression.